Synergistic combination of DT-13 and topotecan inhibits human gastric cancer via myosin IIA-induced endocytosis of egf receptor in vitro and in vivo

Oncotarget

Volumn 7, Issue 22, 2016, Pages 32990-33003

  Yu, Xiao Wen ^a   Lin, Sensen ^a   Du, Hong Zhi ^a   Zhao, Ren Ping ^b   Feng, Shu Yun ^a   Yu, Bo Yang ^c   Zhang, Lu Yong ^a   Li, Rui Ming ^d   Qian, Chang Min ^d   Luo, Xue Jun ^d   Yuan, Sheng Tao ^a   Sun, Li ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b SAARLAND UNIVERSITY   (Germany)

^c Pharmaceutical University   (China)

^d Tasly and Jenner (Tianjin) Co Ltd   (China)

Author keywords

DT 13; EGFR; Gastric cancer; NM IIA; Topotecan

Indexed keywords

BLEBBISTATIN; CASPASE 3; CAVEOLIN 1; DT 13; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MYOSIN IIA; PROTEIN TYROSINE KINASE; SAPONIN; SHORT HAIRPIN RNA; TOPOTECAN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; RUSCOGENIN-1-O-(GLUCOPYRANOSYL-(1-2))(XYLOPYRANOSYL-(1-3))FUCOPYRANOSIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG POTENTIATION; ENDOCYTOSIS; FEMALE; GASTRIC CANCER CELL LINE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN DEGRADATION; STOMACH CANCER; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; DRUG EFFECTS; DRUG SCREENING; HEK293 CELL LINE; METABOLISM; NUDE MOUSE; PATHOLOGY; SIGNAL TRANSDUCTION; STOMACH TUMOR; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; DRUG SYNERGISM; ENDOCYTOSIS; FEMALE; HEK293 CELLS; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NONMUSCLE MYOSIN TYPE IIA; RECEPTOR, EPIDERMAL GROWTH FACTOR; SAPONINS; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; TOPOTECAN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84973560621     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.8843     Document Type: Article

References (43)

1. Deng JY and Liang H. Clinical significance of lymph node metastasis in gastric cancer. World J Gastroentero: WJG. 2014; 20:3967-3975.
2. Cristescu R, Lee J, Nebozhyn M, Kim KM, Ting JC, Wong SS, Liu J, Yue YG, Wang J, Yu K, Ye XS, Do IG, Liu S, Gong L, Fu J, Jin JG, et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med. 2015; 21:449-456.
3. Zhang L, Yang J, Cai J, Song X, Deng J, Huang X, Chen D, Yang M, Wery JP, Li S, Wu A, Li Z, Liu Y, Chen Y, Li Q and Ji J. A subset of gastric cancers with EGFR amplification and overexpression respond to cetuximab therapy. Sci Rep-UK. 2013; 3:2992.
4. Aichler M, Motschmann M, Jutting U, Luber B, Becker K, Ott K, Lordick F, Langer R, Feith M, Siewert JR and Walch A. Epidermal growth factor receptor (EGFR) is an independent adverse prognostic factor in esophageal adenocarcinoma patients treated with cisplatin-based neoadjuvant chemotherapy. Oncotarget. 2014; 5:6620-6632. doi: 10.18632/oncotarget.2268.
5. Wheler J, Falchook G, Tsimberidou AM, Hong D, Naing A, Piha-Paul S, Chen SS, Heymach J, Fu S, Stephen B, Fok JY, Janku F and Kurzrock R. Revisiting clinical trials using EGFR inhibitor-based regimens in patients with advanced non-small cell lung cancer: a retrospective analysis of an MD Anderson Cancer Center phase I population. Oncotarget. 2013; 4:772-784. doi: 10.18632/oncotarget.1028.
6. von Pawel J, Gatzemeier U, Pujol JL, Moreau L, Bildat S, Ranson M, Richardson G, Steppert C, Riviere A, Camlett I, Lane S and Ross G. Phase ii comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer. J Clin Oncol. 2001; 19:1743-1749.
7. Rodriguez M and Rose PG. Improved therapeutic index of lower dose topotecan chemotherapy in recurrent ovarian cancer. Gynecol Oncol. 2001; 83:257-262.
8. Mimaki Y, Takaashi Y, Kuroda M, Sashida Y and Nikaido T. Steroidal saponins from Nolina recurvata stems and their inhibitory activity on cyclic AMP phosphodiesterase. Phytochemistry. 1996; 42:1609-1615.
9. Zhao R, Sun L, Lin S, Bai X, Yu B, Yuan S and Zhang L. The saponin monomer of dwarf lilyturf tuber, DT-13, inhibits angiogenesis under hypoxia and normoxia via multi-targeting activity. Oncol Rep. 2013; 29:1379-1386.
10. Sun L, Lin S, Zhao R, Yu B, Yuan S and Zhang L. The saponin monomer of dwarf lilyturf tuber, DT-13, reduces human breast cancer cell adhesion and migration during hypoxia via regulation of tissue factor. Biol Pharm Bull. 2010; 33:1192-1198.
11. Ren-Ping Z, Sen-Sen L, Yuan ST, Yu BY, Bai XS, Sun L and Zhang LY. DT-13, a saponin of dwarf lilyturf tuber, exhibits anti-cancer activity by down-regulating C-C chemokine receptor type 5 and vascular endothelial growth factor in MDA-MB-435 cells. Chin J Nat Med. 2014; 12:24-29.
12. Zhang Y, Liu J, Kou J, Yu J and Yu B. DT-13 suppresses MDA-MB-435 cell adhesion and invasion by inhibiting MMP-2/9 via the p38 MAPK pathway. Mol Med Rep. 2012; 6:1121-1125.
13. Zhang Y, Sun M, Han Y, Zhai K, Tang Y, Qin X, Cao Z, Yu B and Kou J. The saponin DT-13 Attenuates Tumor Necrosis Factor-alpha-induced Vascular Inflammation Associated with Src/NF-small ka, CyrillicB/MAPK Pathway Modulation. Int J Biol Sci. 2015; 11:970-981.
14. Vicente-Manzanares M, Ma X, Adelstein RS and Horwitz AR. Non-muscle myosin II takes centre stage in cell adhesion and migration. Nat Rev Mol Cell Bio. 2009; 10:778-790.
15. Even-Ram S, Doyle AD, Conti MA, Matsumoto K, Adelstein RS and Yamada KM. Myosin IIA regulates cell motility and actomyosin-microtubule crosstalk. Nat Cell Biol. 2007; 9:299-309.
16. Wilson CA, Tsuchida MA, Allen GM, Barnhart EL, Applegate KT, Yam PT, Ji L, Keren K, Danuser G and Theriot JA. Myosin II contributes to cell-scale actin network treadmilling through network disassembly. Nature. 2010; 465:373-377.
17. Park I, Han C, Jin S, Lee B, Choi H, Kwon JT, Kim D, Kim J, Lifirsu E, Park WJ, Park ZY, Kim do H and Cho C. Myosin regulatory light chains are required to maintain the stability of myosin II and cellular integrity. Biochem J. 2011; 434:171-180.
18. Golomb E, Ma X, Jana SS, Preston YA, Kawamoto S, Shoham NG, Goldin E, Conti MA, Sellers JR and Adelstein RS. Identification and characterization of nonmuscle myosin II-C, a new member of the myosin II family. J Biol Chem. 2004; 279:2800-2808.
19. Kim KY, Kovacs M, Kawamoto S, Sellers JR and Adelstein RS. Disease-associated mutations and alternative splicing alter the enzymatic and motile activity of nonmuscle myosins II-B and II-C. J Biol Chem. 2005; 280:22769-22775.
20. Nakasawa T, Takahashi M, Matsuzawa F, Aikawa S, Togashi Y, Saitoh T, Yamagishi A and Yazawa M. Critical regions for assembly of vertebrate nonmuscle myosin II. Biochemistry-US. 2005; 44:174-183.
21. Kim JH, Wang A, Conti MA and Adelstein RS. Nonmuscle myosin II is required for internalization of the epidermal growth factor receptor and modulation of downstream signaling. J Biol Chem. 2012; 287:27345-27358.
22. Zuco V, Supino R, Favini E, Tortoreto M, Cincinelli R, Croce AC, Bucci F, Pisano C and Zunino F. Efficacy of ST1968 (namitecan) on a topotecan-resistant squamous cell carcinoma. Biochem Pharmacol. 2010; 79:535-541.
23. Bao Q and Shi Y. Apoptosome: a platform for the activation of initiator caspases. Cell Death Differ. 2007; 14:56-65.
24. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Franklin RA, Montalto G, Cervello M, Libra M, Candido S, Malaponte G, Mazzarino MC, Fagone P, Nicoletti F, et al. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. Oncotarget. 2012; 3:1068-1111. doi: 10.18632/oncotarget.659.
25. Haydn JM, Hufnagel A, Grimm J, Maurus K, Schartl M and Meierjohann S. The MAPK pathway as an apoptosis enhancer in melanoma. Oncotarget. 2014; 5:5040-5053. doi: 10.18632/oncotarget.2079.
26. Abulrob A, Giuseppin S, Andrade MF, McDermid A, Moreno M and Stanimirovic D. Interactions of EGFR and caveolin-1 in human glioblastoma cells: evidence that tyrosine phosphorylation regulates EGFR association with caveolae. Oncogene. 2004; 23:6967-6979.
27. Agelaki S, Spiliotaki M, Markomanolaki H, Kallergi G, Mavroudis D, Georgoulias V and Stournaras C. Caveolin-1 regulates EGFR signaling in MCF-7 breast cancer cells and enhances gefitinib-induced tumor cell inhibition. Cancer Biol Ther. 2009; 8:1470-1477.
28. Chatterjee M, Ben-Josef E, Thomas DG, Morgan MA, Zalupski MM, Khan G, Andrew Robinson C, Griffith KA, Chen CS, Ludwig T, Bekaii-Saab T, Chakravarti A and Williams TM. Caveolin-1 is Associated with Tumor Progression and Confers a Multi-Modality Resistance Phenotype in Pancreatic Cancer. Sci Rep-UK. 2015; 5:10867.
29. Thomas S, Overdevest JB, Nitz MD, Williams PD, Owens CR, Sanchez-Carbayo M, Frierson HF, Schwartz MA and Theodorescu D. Src and caveolin-1 reciprocally regulate metastasis via a common downstream signaling pathway in bladder cancer. Cancer Res. 2011; 71:832-841.
30. Joshi B, Strugnell SS, Goetz JG, Kojic LD, Cox ME, Griffith OL, Chan SK, Jones SJ, Leung SP, Masoudi H, Leung S, Wiseman SM and Nabi IR. Phosphorylated caveolin-1 regulates Rho/ROCK-dependent focal adhesion dynamics and tumor cell migration and invasion. Cancer Res. 2008; 68:8210-8220.
31. Chang CC, Yang MH, Lin BR, Chen ST, Pan SH, Hsiao M, Lai TC, Lin SK, Jeng YM, Chu CY, Chen RH, Yang PC, Chin YE and Kuo ML. CCN2 inhibits lung cancer metastasis through promoting DAPK-dependent anoikis and inducing EGFR degradation. Cell Death Differ. 2013; 20:443-455.
32. Wu W, Wages PA, Devlin RB, Diaz-Sanchez D, Peden DB and Samet JM. SRC-mediated EGF receptor activation regulates ozone-induced interleukin 8 expression in human bronchial epithelial cells. Environ Health Persp. 2015; 123:231-236.
33. Zwitter M, Rajer M, Kovac V, Kern I, Vrankar M and Smrdel U. Intermittent chemotherapy and erlotinib for nonsmokers or light smokers with advanced adenocarcinoma of the lung: a phase II clinical trial. J Biomed Biotechnol. 2011; 2011:185646.
34. Zhou Y, Liang C, Xue F, Chen W, Zhi X, Feng X, Bai X and Liang T. Salinomycin decreases doxorubicin resistance in hepatocellular carcinoma cells by inhibiting the beta-catenin/ TCF complex association via FOXO3a activation. Oncotarget. 2015; 6:10350-10365. doi: 10.18632/oncotarget.3585.
35. Okabe T, Okamoto I, Tsukioka S, Uchida J, Hatashita E, Yamada Y, Yoshida T, Nishio K, Fukuoka M, Janne PA and Nakagawa K. Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplification. Clin Cancer Res. 2009; 15:907-913.
36. Khazak V, Astsaturov I, Serebriiskii IG and Golemis EA. Selective Raf inhibition in cancer therapy. Expert opin ther tar. 2007; 11:1587-1609.
37. Xu TR, Vyshemirsky V, Gormand A, von Kriegsheim A, Girolami M, Baillie GS, Ketley D, Dunlop AJ, Milligan G, Houslay MD and Kolch W. Inferring signaling pathway topologies from multiple perturbation measurements of specific biochemical species. Sci signal. 2010; 3:ra20.
38. Henriksen L, Grandal MV, Knudsen SL, van Deurs B and Grovdal LM. Internalization mechanisms of the epidermal growth factor receptor after activation with different ligands. PloS one. 2013; 8:e58148.
39. Wilde A, Beattie EC, Lem L, Riethof DA, Liu SH, Mobley WC, Soriano P and Brodsky FM. EGF receptor signaling stimulates SRC kinase phosphorylation of clathrin, influencing clathrin redistribution and EGF uptake. Cell. 1999; 96:677-687.
40. Sigismund S, Argenzio E, Tosoni D, Cavallaro E, Polo S and Di Fiore PP. Clathrin-mediated internalization is essential for sustained EGFR signaling but dispensable for degradation. Dev Cell. 2008; 15:209-219.
41. Maldonado-Baez L and Wendland B. Endocytic adaptors: recruiters, coordinators and regulators. Trends Cell Biol. 2006; 16:505-513.
42. Mayor S and Pagano RE. Pathways of clathrin-independent endocytosis. Nat Rev Mol Cell Bio. 2007; 8:603-612.
43. Terashima M, Kitada K, Ochiai A, Ichikawa W, Kurahashi I, Sakuramoto S, Katai H, Sano T, Imamura H and Sasako M. Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer. Clin Cancer Res. 2012; 18:5992-6000.